Canadian Pharmacare Report Urges Mandatory Substitution
Recommendations by Canada’s advisory council implementing national pharmacare include mandatory generic substitution and also mechanisms of biosimilar substitution.
You may also be interested in...
An agreement between industry and authorities in effect from April last year is already having a major effect in ensuring Canadian generics prices are similar to those in other developed markets, an official report shows.
Originator-backed lobbying group the Alliance for Safe Biologic Medicines has raised concerns over a biosimilar switching policy recently unveiled by the Canadian province of British Columbia.
Generics prices in Canada have seen the steepest decline of all OECD countries, the CGPA has highlighted following the release of the latest PMPRB data.